Market Cap | 5.28B | P/E | - | EPS this Y | - | Ern Qtrly Grth | 189.70% |
Income | 2.5M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 9.00% |
Sales | 379.7M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 37.00% |
Dividend | N/A | Price/Book | 7.24 | EPS next 5Y | 0.35% | 52W High Chg | -9.00% |
Recommedations | 3.00 | Quick Ratio | 0.99 | Shares Outstanding | 230.15M | 52W Low Chg | 84.00% |
Insider Own | 6.44% | ROA | 4.36% | Shares Float | 192.43M | Beta | 0.86 |
Inst Own | 88.22% | ROE | 0.35% | Shares Shorted/Prior | 4.08M/2.90M | Price | 22.98 |
Gross Margin | 75.88% | Profit Margin | 0.66% | Avg. Volume | 1,842,374 | Target Price | 1,902.05 |
Oper. Margin | 18.31% | Earnings Date | - | Volume | 1,567,445 | Change | -0.82% |
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam plc operates as a subsidiary of Danaher Corporation.
RBC Capital | Sector Perform | Oct 31, 23 |
RBC Capital | Sector Perform | Oct 9, 23 |
SVB Leerink | Market Perform | Aug 30, 23 |
RBC Capital | Sector Perform | Aug 22, 23 |
RBC Capital | Sector Perform | Jun 20, 23 |
B of A Securities | Buy | Jun 16, 23 |
Morgan Stanley | Equal-Weight | Jun 12, 23 |
RBC Capital | Outperform | Apr 28, 23 |
Deutsche Bank | Hold | Mar 22, 23 |